Evidence map›Paper›PMID 38592684›Full record

ArticleBioconjugate chemistry2024

Adapting Ferritin, a Naturally Occurring Protein Cage, to Modulate Intrinsic Agonism of OX40.

Whitney Shatz-Binder, Caleigh M Azumaya, Brandon Leonard, Ivan Vuong, Jawahar Sudhamsu, Alexis Rohou, Peter Liu, Wendy Sandoval, Karenna Bol, Saeed Izadi and 5 more

Abstract read
In one paragraph

Article in Bioconjugate chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Whitney Shatz-BinderProtein Chemistry, Genentech Inc., South San Francisco, California 94080, United States.ORCID 0000-0003-2996-501X
Caleigh M AzumayaStructural Biology, Genentech Inc., South San Francisco, California 94080, United States.ORCID 0000-0002-3484-9921
Brandon LeonardAntibody Engineering, Genentech Inc., South San Francisco, California 94080, United States.
Ivan VuongProtein Chemistry, Genentech Inc., South San Francisco, California 94080, United States.
Jawahar SudhamsuStructural Biology, Genentech Inc., South San Francisco, California 94080, United States.
Alexis RohouStructural Biology, Genentech Inc., South San Francisco, California 94080, United States.ORCID 0000-0002-3343-9621
Peter LiuMicrochemistry, Proteomics and Lipidomics, Genentech Inc., South San Francisco, California 94080, United States.
Wendy SandovalMicrochemistry, Proteomics and Lipidomics, Genentech Inc., South San Francisco, California 94080, United States.
Karenna BolPharmaceutical Chemistry, Genentech Inc., South San Francisco, California 94080, United States.
Saeed IzadiPharmaceutical Chemistry, Genentech Inc., South San Francisco, California 94080, United States.
Patrick G HolderProtein Chemistry, Genentech Inc., South San Francisco, California 94080, United States.ORCID 0000-0003-0971-191X
Craig BlanchetteProtein Chemistry, Genentech Inc., South San Francisco, California 94080, United States.
Remo PerozzoPharmaceutical Sciences, University of Geneva, Geneva 1211, Switzerland.
Robert F KelleyPharmaceutical Chemistry, Genentech Inc., South San Francisco, California 94080, United States.ORCID 0000-0002-2103-3931
Yogeshvar KaliaPharmaceutical Sciences, University of Geneva, Geneva 1211, Switzerland.ORCID 0000-0001-9049-5489

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferritin is a multivalent, self-assembling protein scaffold found in most human cell types, in addition to being present in invertebrates, higher plants, fungi, and bacteria, that offers an attractive alternative to polymer-based drug delivery systems (DDS). In this study, the utility of the ferritin cage as a DDS was demonstrated within the context of T cell agonism for tumor killing. Members of the tumor necrosis factor receptor superfamily (TNFRSF) are attractive targets for the development of anticancer therapeutics. These receptors are endogenously activated by trimeric ligands that occur in transmembrane or soluble forms, and oligomerization and cell-surface anchoring have been shown to be essential aspects of the targeted agonism of this receptor class. Here, we demonstrated that the ferritin cage could be easily tailored for multivalent display of anti-OX40 antibody fragments on its surface and determined that these arrays are capable of pathway activation through cell-surface clustering. Together, these results confirm the utility, versatility, and developability of ferritin as a DDS.

Indexed as

FerritinsDrug Delivery SystemsHumansT-LymphocytesFerritins

Identifiers

PMID38592684
PMCPMC11099885

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.